Generian Pharmaceuticals has signed a collaboration and exclusive license agreement with Astellas Pharma’s wholly owned subsidiary Mitobridge for the research and development of new small molecules for undruggable therapeutic targets.
Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered into a strategic collaboration for the development and commercialisation of two bifunctional sialidase therapies.
ImmunoGen and Oxford BioTherapeutics (OBT) have entered into a multi-year research collaboration to develop new antibody-drug conjugates (ADCs) to treat cancers.
Olema Pharmaceuticals (Olema Oncology) has announced an exclusive global license agreement with Aurigene Discovery Technologies to discover, develop, and commercialise new cancer therapies.
Biotech company Upstream Bio has raised $200m in Series A financing round to advance development of new therapeutics for allergic and inflammatory diseases.
Sapience Therapeutics has raised $41m in a Series B funding round to advance the pipeline of peptide therapeutics targeting protein-protein interactions.
AI drug discovery firm PharmEnable and biopharmaceutical company Denali Therapeutics have entered into a multi-target collaboration to accelerate drug discovery in neurodegenerative diseases.
Novartis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Cosentyx (secukinumab) for usage either alone or in combination with methotrexate.
CBDepot produces high-quality natural cannabinoid ingredients and cannabinoid-enriched products for the industrial and consumer market.
BenevolentAI and Drugs for Neglected Disease initiative (DNDi) have commenced a joint AI research project to address dengue.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.